AngelMed Announces First Implant of Next-Generation AngelMed Guardian® in the U.S.
EATONTOWN, N.J., Sept. 30, 2020 /PRNewswire/ -- AngelMed is pleased to announce that on Tuesday, September 29th, a former ALERTS Study patient in the United States received the first implant of the next-generation AngelMed Guardian® System as part of the ALERTS-Continued Access Study. The AngelMed Guardian is the only implantable, patient alerting system designed to warn patients to seek medical attention for acute coronary syndromes (ACS), including heart attacks.
The implant of the newly refined AngelMed Guardian was performed by Kelly Tucker, M.D., Director, Electrophysiology, Orange County Heart Institute and Research Center at Pavilion Surgery Center in Orange, CA.
"The AngelMed Guardian represents a real game changer in the management of coronary artery disease. This is the first ever surveillance tool for patients with a prior coronary event and has the potential to save countless lives and bring peace of mind to thousands of families. It is a great honor to be involved in this amazing technology," said Kelly Tucker, M.D.
According to the American Heart Association, the estimated annual incidence of heart attack in the US was 605,000 new and 200,000 recurrent attacks. Studies have shown that at least 25% of MIs are unrecognized or silent.
The AngelMed Guardian system is designed to track significant changes in the heart's electrical signal and then alert patients to seek medical attention – this includes detection of silent heart attacks. The objective of the ALERTS-Continued Access Study is to provide former ALERTS patients access to this life-changing device.
AngelMed CEO Gordie Nye commented, "We are thankful to the FDA for allowing us to perform this study so that our previous ALERTS patients may get the AngelMed Guardian back. These pioneers still to this day remain pivotal to our success and we as a company are excited for the road ahead as we move closer to commercialization."
Pavilion Surgery Center and Orange County Heart Institute and Research Center is the first medical facility to participate in the AngelMed Guardian ALERTS-Continued Access study.
Dr. David Fischell, Founder and Chairman of AngelMed added, "Tremendous thanks to Dr. Tucker and the entire AngelMed team that made today's implant possible. However, for me, it has always been first and foremost about our patients. We are specially pleased to be able to begin re-implanting our ALERTS patients whose willingness to participate in our clinical trial was critical to obtaining FDA approval for the Guardian System. This is the start of a brighter future for ACS and heart attack survivors in the United States."
About Angel Medical Systems, Inc.
Forward Looking Statements
View original content to download multimedia:http://www.prnewswire.com/news-releases/angelmed-announces-first-implant-of-next-generation-angelmed-guardian-in-the-us-301142021.html
SOURCE Angel Medical Systems